Novartis to use gene editing tool with CAR-T therapies
This article was originally published in Scrip
Novartis has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using the CRISPR genome editing technology. It simultaneously entered a deal with Caribou Biosciences for the development of drug discovery tools in the nascent field.
You may also be interested in...
Intellia, Cellex Team Up On New CAR-T Firm, Backed By Blackstone
Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.
The Case For CAR-T Grows As Responses Hold Up Longer Term
Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.